Back
#1
18.1%
Top 7%
12.1%
Top 2%
11.2%
Top 1%
8.0%
Top 10%
4.3%
Top 65%
4.0%
Top 2%
2.9%
Top 2%
2.9%
Top 90%
2.9%
Top 2%
2.0%
Top 9%
2.0%
Top 6%
2.0%
Top 1%
2.0%
Top 6%
2.0%
Top 2%
1.6%
Top 8%
1.6%
Top 5%
1.6%
Top 0.6%
1.4%
Top 7%
1.0%
Top 3%
1.0%
Top 7%
0.7%
Top 7%
0.7%
Top 17%
0.7%
Top 6%
0.5%
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations
2025-07-21
oncology
Title + abstract only
View on medRxiv
Show abstract
BackgroundCancers that do not respond to immunotherapy typically harbor a non-T cell-inflamed tumor microenvironment (TME), characterized by the absence of type I/II interferon (IFN) signaling and CD8+ T cell infiltration. We previously reported IDH1 somatic mutations were enriched in non-T cell-inflamed tumors across tumor types. Consistent with this, mutant IDH1 (mIDH1) has been demonstrated to drive immune exclusion through metabolic reprogramming of the TME, and IDH inhibition enhanced anti-...
Predicted journal destinations
1
Clinical Cancer Research
22 training papers
2
Nature Communications
483 training papers
3
Cancers
57 training papers
4
Frontiers in Oncology
34 training papers
5
eLife
262 training papers
6
Scientific Reports
701 training papers
7
Cancer Medicine
17 training papers
8
British Journal of Cancer
22 training papers
9
PLOS ONE
1737 training papers
10
BMC Cancer
21 training papers
11
JAMA Network Open
125 training papers
12
Frontiers in Immunology
140 training papers
13
Cell Reports Medicine
49 training papers
14
Nature Genetics
72 training papers
15
Journal of Clinical Investigation
50 training papers
16
Proceedings of the National Academy of Sciences
100 training papers
17
iScience
74 training papers
18
Cell Reports
25 training papers
19
Nature
58 training papers
20
Communications Biology
36 training papers
21
International Journal of Molecular Sciences
39 training papers
22
Communications Medicine
63 training papers
23
Nature Medicine
88 training papers
24
Science Translational Medicine
40 training papers